The inspection of the Sanofi (SNY) Pasteur facility located at 1541 avenue Marcel Merieux in Marcy-l’Etoile in France, conducted from June 16 to 20, 2025, revealed significant non-conformities and deficiencies, the French regulatory that oversees the safety of health products said. These were notified to the facility in a preliminary injunction letter dated August 26, 2025. Following this inspection and the responses provided by the facility on September 11, September 24, and October 16, 2025, the ANSM said there was unsatisfactory management of contamination; a lack of control in managing the risk of cross-contamination; problems receiving and qualifying raw materials, and deficiencies in managing subcontractors. The company subsequently attempted to address the issues, but failed to do so, according to ANSM, which wants various corrective steps to be implemented over the next nine months.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- FDA appoints Richard Pazdur as Director of CDER
- Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study
- Regeneron, Sanofi announces presentation of Phase 3 trial of Dupixent
- Dianthus price target raised to $62 from $60 at Oppenheimer